At three years postoperatively, the Fixoflex™ IOL demonstrated a significantly lower incidence of PCO and reduced need for Nd:YAG capsulotomy compared to the control group. Visual outcomes remained stable, with minimal refractive shift and well-maintained CDVA. Additionally, safety values were comparable for both groups indicating that the device is safe. These findings suggest that Fixoflex™ offers long-term stability and may contribute to improved posterior capsule clarity, potentially reducing the need for secondary interventions.
Three-Year Follow-Up Of Cataract Patients With Fixoflextm
Published 2025 - 43rd Congress of the ESCRS
Reference: PO335 | Type: Free paper | DOI: 10.82333/h8sv-qc26
Authors: Nabila Jones 1 , Clare ODonnell* 2 , Amir Hamid 3
1Eye Sciences,Optegra Eye Health Care,Manchester,United Kingdom, 2Eye Sciences,Optegra Eye Health Care,Manchester,United Kingdom;Faculty of Biology, Medicine and Health,University of Manchester,Manchester,United Kingdom;College of Health and Life Sciences,Aston University,Birmingham,United Kingdom, 3Eye Sciences,Optegra Eye Health Care,Manchester,United Kingdom;Faculty of Biology, Medicine and Health,University of Manchester,Manchester,United Kingdom
Purpose
To present the clinical outcomes and observations from a three-year postoperative follow-up of 68 patients who underwent implantation of the fixOflexTM and a monofocal intraocular lens (IOL) (Tecnis ZCB00, Johnson & Johnson Vision), compared to a control group who received conventional cataract surgery with the same IOL.
Setting
Ophthalmology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Methods
Cataract patients who underwent crystalline lens extraction by phacoemulsification and were implanted with a monofocal intraocular lens (IOL) (Tecnis ZCB00, Johnson & Johnson Vision) between 2020 and July 2021 were enrolled in this study. A total of 68 eyes were included in the group with the endocapsular device, while the control group, without the device, comprised 59 eyes.
The examination included: preoperative and postoperative UDVA, CDVA, intraocular pressure (IOP), endothelial cell density and loss (ECD and ECL), posterior capsular opacification (PCO) assessment and perioperative and postoperative complications
Results
At the 3-year follow-up, the incidence of PCO was significantly lower in the Fixoflex™ group (1.47%) compared to the control group (32.35%). Similarly, the need for Nd:YAG capsulotomy was reduced in the Fixoflex™ group (1.47%) versus the control (13.56%). Visual outcomes remained stable in both cohorts. The Fixoflex™ group exhibited a minimal change in spherical equivalent (SE) between 1 and 3 years (-0.02 ± 0.007 D), while the control group showed a shift of 0.04 ± 0.006 D. The change in UDVA (LogMAR) was 0.05 ± 0.009 in the Fixoflex™ group, compared to 0.02 ± 0.011 in the control. CDVA remained well-maintained, with the Fixoflex™ group achieving 0.05 ± 0.08 at 3 years vs. 0.09 ± 0.14 in the control group. IOP, and ECL were comparable.
Conclusions